Ireland
UK
Scotland
London
Marama Labs, a life-sciences instrumentation startup, has secured €280,000 in funding from Enterprise Ireland to expand its operations in Ireland. This investment is part of Enterprise Ireland's High Potential Start-Up (HPSU) program and contributes to the company’s €2 million seed-plus round for Q4 2023, led by the prominent Irish venture capital firm The Yield Lab Europe.
Founded in New Zealand in 2019, Marama Labs is headed by Irish-born CEO and co-founder Dr. Brendan Darby, with offices located in Dublin and Wellington, New Zealand.
The investment from Enterprise Ireland will be used to fund the expansion of Marama Labs’ Irish operations, opening a commercially-focused applications lab in North Dublin and hiring a life-sciences applications team to support its customers in the Northern Hemisphere.
Dr Brendan Darby, CEO and Co-Founder of Marama Labs, said: "We are delighted to have secured investment from Enterprise Ireland as part of our recent capital raise. Ireland’s position as a leader in the global life sciences industry provides the perfect launchpad for Marama Labs to scale our commercial footprint in the Northern Hemisphere life sciences market. I am personally very excited about working with Enterprise Ireland to build out our Irish activities and leverage the unique life sciences skills available in Ireland.
"Our mission is to become a global leader in scientific instrumentation, removing bottlenecks in the chemical analysis of liquids, enabling faster and cheaper development of life-saving products."
Tom Kelly, Divisional Manager, Industrial & Life Sciences at Enterprise Ireland said: "Congratulations to the team at Marama Labs on its recent investment wins. Enterprise Ireland's HPSU investment in this highly innovative company will support its exploration into the rapidly growing life-sciences market and the expansion of its operations in Ireland."
Marama Labs develops novel spectroscopy technology that can rapidly analyse the chemistry of highly complex high-value liquids in industries such as life sciences and fermentation. Its CloudSpec product is able to quantify crucial quality information about new classes of therapeutics, called nanomedicines, in seconds, compared to hours it takes with existing technologies.
